SynthesisBMC infectious diseases2025

Efficacy and safety of imipenem/cilastatin/relebactam (IMI/CS/REL): a meta-analysis of randomized controlled clinical trials.

Wenjuan Lei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.